News | January 28, 2023
Aarti Drugs Q3 FY23 revenue grows 4%
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
The goal of Dozee’s partnership with BII is to improve access to healthcare across India and alleviate the workload of healthcare workers, reduce nurse burnout and fatigue in hospital wards
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
In a time when conversations around mental health have become ever more urgent Vaidya’s work is extremely contextual
Subscribe To Our Newsletter & Stay Updated
